Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 1228

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 13
Chunk 1228
---
    31, 2025
  
    J.
    Michael Edwards
     
    (Principal
    Financial and Accounting Officer)

    /s/
    Steven Girgenti
     
    Executive
    Chairman and Director
     
    March
    31, 2025
  
    Steven
    Girgenti

    /s/
    Robert Anderson
     
    Director
     
    March
    31, 2025
  
    Robert
    Anderson

    /s/
    Stuart Diamond
     
    Director
     
    March
    31, 2025
  
    Stuart
    Diamond

    /s/
    Peter S. Knight
     
    Director
     
    March
    31, 2025
  
    Peter
    S. Knight

    /s/
    Gary Rubin 
     
    Director
     
    March
    31, 2025
  
    Gary
    Rubin

    /s/
    Roby Joyce, M.D.
     
    Director
     
    March
    31, 2025
  
    Roby
    Joyce

    /s/
    Jamie Platt
     
    Director
     
    March
    31, 2025
  
    Jamie
    Platt

 70 

bioAffinity
Technologies, Inc.

Index
to the Consolidated Financial Statements

    Report of Independent Registered Public Accounting Firm (PCAOB ID NO. 100)
    F-2

    Consolidated Balance Sheets as of December 31, 2024 and 2023
    F-3

    Consolidated Statements of Operations for the years ended December 31, 2024 and 2023
    F-4

    Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity for the years ended December 31, 2024 and 2023
    F-5

    Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023
    F-6

    Notes to Consolidated Financial Statements
    F-7

F-1

Report
of Independent Registered Public Accounting Firm

To
the Board of Directors and Stockholders of

bioAffinity
Technologies, Inc.:

Opinion
on the Consolidated Financial Statements

We
have audited the accompanying consolidated balance sheets of bioAffinity Technologies, Inc. (the “Company”) as